Sarepta Therapeutics (SRPT) Stock: Gains On Coming FDA Advisory Committee Meeting

0

Sarepta Therapeutics Inc (NASDAQ: SRPT) is having a strong day in the market today after the FDA announced a forthcoming Pediatric Advisory Committee meeting. The meeting led to excitement among investors and sent the stock upward. As is nearly always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:24), SRPT is trading at $33.14 per share after a gain of $0.53 per share (1.64%) thus far today.





SRPT Gains On Coming FDA Advisory Committee Meeting

As mentioned above, Sarepta Therapeutics is having a strong start to the trading session today after the FDA announced that a Pediatric Advisory Committee meeting is coming soon. In the meeting, the FDA and the Pediatric Advisory Committee will discuss SRP-4045 and SRP-4053. Here’s a quick summary from the FDA release with regard to the SRPT meeting:




The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC) and the Pediatric Ethics Subcommittee (PES). The general function of the committees is to provide advice and make recommendations to the Agency on pediatric ethical issues. The meeting will be open to the public.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SRPT. In particular, we’ll be paying close attention to the advisory committee meeting and what the result of the meeting means for the company. We’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

LEAVE A REPLY

Please enter your comment!
Please enter your name here